[{"address1": "1000 Skokie Boulevard", "address2": "Suite 350", "city": "Wilmette", "state": "IL", "zip": "60091", "country": "United States", "phone": "847 388 0349", "website": "https://www.monopartx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher M. Starr Ph.D.", "age": 72, "title": "Co-Founder & Independent Executive Chairman of the Board", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 200000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc", "age": 40, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 710500, "exercisedValue": 0, "unexercisedValue": 56986}, {"maxAge": 1, "name": "Mr. Andrew J. Cittadine M.B.A.", "age": 52, "title": "Chief Operating Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 416700, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Karthik  Radhakrishnan CFA", "age": 53, "title": "CFO, Principal Accounting Officer & Principal Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Patrice P. Rioux M.D., Ph.D.", "age": 73, "title": "Acting Chief Medical Officer", "yearBorn": 1951, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 44.68, "open": 43.0, "dayLow": 39.7212, "dayHigh": 43.6016, "regularMarketPreviousClose": 44.68, "regularMarketOpen": 43.0, "regularMarketDayLow": 39.7212, "regularMarketDayHigh": 43.6016, "beta": 1.315, "forwardPE": -17.4024, "volume": 57487, "regularMarketVolume": 57487, "averageVolume": 79006, "averageVolume10days": 75220, "averageDailyVolume10Day": 75220, "bid": 40.95, "ask": 44.64, "bidSize": 100, "askSize": 100, "marketCap": 263019040, "fiftyTwoWeekLow": 1.72, "fiftyTwoWeekHigh": 54.3, "fiftyDayAverage": 31.429, "twoHundredDayAverage": 12.522975, "currency": "USD", "enterpriseValue": 221452928, "floatShares": 2890068, "sharesOutstanding": 6102530, "sharesShort": 30636, "sharesShortPriorMonth": 36448, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.005, "heldPercentInsiders": 0.37011, "heldPercentInstitutions": 0.45527, "shortRatio": 0.49, "shortPercentOfFloat": 0.01, "impliedSharesOutstanding": 6102530, "bookValue": 1.403, "priceToBook": 30.719885, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -6474726, "trailingEps": -1.98, "forwardEps": -2.36, "lastSplitFactor": "1:5", "lastSplitDate": 1723507200, "52WeekChange": 12.357249, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MNPR", "underlyingSymbol": "MNPR", "shortName": "Monopar Therapeutics Inc.", "longName": "Monopar Therapeutics Inc.", "firstTradeDateEpochUtc": 1576765800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "4c85e6c0-debc-355c-95b2-bf3324d36ecc", "messageBoardId": "finmb_304391755", "gmtOffSetMilliseconds": -18000000, "currentPrice": 43.1, "targetHighPrice": 72.0, "targetLowPrice": 37.0, "targetMeanPrice": 52.25, "targetMedianPrice": 50.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 6020084, "totalCashPerShare": 1.141, "quickRatio": 5.361, "currentRatio": 5.405, "returnOnAssets": -0.59667, "returnOnEquity": -1.12038, "freeCashflow": -3873349, "operatingCashflow": -5951620, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]